Stimolazione per migliorare la memoria (STIM)
Test della stimolazione transcranica a corrente continua ad alta definizione (HD-tDCS) come trattamento del lieve deterioramento cognitivo
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
Tipo di studio
Tipo di studio
Iscrizione (Effettivo)
Iscrizione
Fase
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: Stephen M Schlaefflin, BS
- Numero di telefono: 734-936-7360
- Email: schlst@med.umich.edu
Backup dei contatti dello studio
- Nome: Eileen A Robinson, RN-BC
- Numero di telefono: 734-763-1356
- Email: robinsoe@med.umich.edu
Luoghi di studio
-
-
Michigan
-
Ann Arbor, Michigan, Stati Uniti, 48105
- University of Michigan
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Descrizione
Criterio di inclusione:
- Diagnosi di Mild Cognitive Impairment (MCI) o demenza di tipo Alzheimer (DAT)
- Deve essere compatibile con la risonanza magnetica, criteri che si applicano anche alla stimolazione transcranica a corrente continua ad alta definizione (HD-tDCS; ad esempio, assenza di impianti metallici o elettronici nella parte superiore del corpo o nella testa)
- Stabile sui farmaci pertinenti per almeno 4 settimane prima dell'arruolamento nello studio
Criteri di esclusione:
- Alcune malattie neurologiche
- Alcune condizioni psichiatriche
- Grave compromissione sensoriale
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Triplicare
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Comparatore fittizio: Stimolazione fittizia
Sham (placebo) dose di trattamento HD-tDCS per 30 minuti, per un periodo compreso tra 5 e 30 sessioni.
|
I partecipanti riceveranno un finto (placebo) HD-tDCS per 30 minuti, per un periodo compreso tra 5 e 30 sessioni.
|
|
Sperimentale: 1 mA Dosaggio Stimolazione
1 dose milliAmp di trattamento HD-tDCS per 30 minuti, per un periodo compreso tra 5 e 30 sessioni.
|
I partecipanti riceveranno HD-tDCS a 1 mA per 30 minuti, per 5-30 sessioni.
|
|
Sperimentale: Stimolazione del dosaggio 2 mA
Dose da 2 milliAmp di trattamento HD-tDCS per 30 minuti, per un periodo compreso tra 5 e 30 sessioni.
|
I partecipanti riceveranno HD-tDCS a 2 mA per 30 minuti, per 5-30 sessioni.
|
|
Sperimentale: Stimolazione del dosaggio 3 mA
Dose da 3 milliAmp di trattamento HD-tDCS per 30 minuti, per un periodo compreso tra 5 e 30 sessioni.
|
I partecipanti riceveranno HD-tDCS a 3 mA per 30 minuti, per 5-30 sessioni.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in Lateral Temporal Cortex Connectivity
Lasso di tempo: Change from Baseline to Post-Intervention (after tDCS Session 5 - day 5 of treatment) and from Baseline to Post-Expansion (after the participant's final tDCS session beyond Session 5, up to 43 weeks).
|
Primary outcome focuses on default mode network (DMN) between-network functional connectivity because the lateral temporal cortex is a core component of the DMN.
Between-network functional connectivity is estimated from fMRI data as strength of temporal coupling between the DMN and other high-level (association) brain networks.
For each participant and time point, correlation-based connectivity (Pearson r; Fisher r-to-z transformed; arbitrary units) computed between DMN regions and other regions of the association cortex defined using standard functional atlas.
Higher values reflect stronger functional connectivity between DMN and other regions.
A Z-score's range is infinite.
Expected value is between -3 to 3. Analyses conducted separately for amyloid negative (A-) and amyloid positive (A+) participants.
Post Intervention data collection was on day 5 of treatment.
Post-Expansion (PE) appointments were not consecutive.
Mean time between enrollment and PE was 10 wks, longest was 43 wks.
|
Change from Baseline to Post-Intervention (after tDCS Session 5 - day 5 of treatment) and from Baseline to Post-Expansion (after the participant's final tDCS session beyond Session 5, up to 43 weeks).
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Self-Report of Contentment With Memory
Lasso di tempo: Change from Baseline to Post-Intervention (after tDCS Session 5 - day 5 of treatment) and from Baseline to Post-Expansion (after the participant's final tDCS session beyond Session 5, up to 43 weeks).
|
The Multifactorial Memory Questionnaire (MMQ) consists of three scales measuring separate aspects of metamemory. Items are rated on a 5-point Likert scale (0-4) based on the test taker's experiences over the previous two weeks. MMQ-Satisfaction (formerly called MMQ-Contentment) scale measures satisfaction, concern, and overall appraisal of one's own memory. Each of 18 statements is rated based on degree of agreement. The score range is 0 to 72, with higher scores indicating a higher degree of satisfaction. Post Intervention data collection was on day 5 of treatment. Post-Expansion (PE) appointments were not consecutive. Mean time between enrollment and PE was 10 wks, longest was 43 wks. |
Change from Baseline to Post-Intervention (after tDCS Session 5 - day 5 of treatment) and from Baseline to Post-Expansion (after the participant's final tDCS session beyond Session 5, up to 43 weeks).
|
|
Self-Report of Memory Mistakes
Lasso di tempo: Change from Baseline to Post-Intervention (after tDCS Session 5 - day 5 of treatment) and from Baseline to Post-Expansion (after the participant's final tDCS session beyond Session 5, up to 43 weeks).
|
Multifactorial Memory Questionnaire (MMQ) Ability Score - This scale measures self-perception of everyday memory ability. Respondents rate how often they experienced each of 20 common memory mistakes over the previous two weeks. The score range is 0 to 80, with higher scores indicating better self-reported memory ability. Post Intervention data collection was on day 5 of treatment. Post-Expansion (PE) appointments were not consecutive. Mean time between enrollment and PE was 10 wks, longest was 43 wks. |
Change from Baseline to Post-Intervention (after tDCS Session 5 - day 5 of treatment) and from Baseline to Post-Expansion (after the participant's final tDCS session beyond Session 5, up to 43 weeks).
|
|
Self-Report of Memory Strategies Used
Lasso di tempo: Change from Baseline to Post-Intervention (after tDCS Session 5 - day 5 of treatment) and from Baseline to Post-Expansion (after the participant's final tDCS session beyond Session 5, up to 43 weeks).
|
Multifactorial Memory Questionnaire (MMQ) Strategies Score - This scale measures the use of practical memory strategies and aids in day-to-day life. Respondents rate how often they used each of 19 memory strategies over the previous two weeks. The score range is 0 to 76, with higher scores indicating greater use of memory strategies. Post Intervention data collection was on day 5 of treatment. Post-Expansion (PE) appointments were not consecutive. Mean time between enrollment and PE was 10 wks, longest was 43 wks. |
Change from Baseline to Post-Intervention (after tDCS Session 5 - day 5 of treatment) and from Baseline to Post-Expansion (after the participant's final tDCS session beyond Session 5, up to 43 weeks).
|
|
Change in Memory Functioning
Lasso di tempo: Change from Baseline to Post-Intervention (after tDCS Session 5 - day 5 of treatment) and from Baseline to Post-Expansion (after the participant's final tDCS session beyond Session 5, up to 43 weeks).
|
The Repeatable Battery of the Assessment of Neuropsychological Status (RBANS) is a comprehensive neuropsychological battery for the evaluation of global cognition.
The delayed memory section is a measure of delayed recall and recognition for verbal and visual information.
It includes the subtests List Recall, List Recognition, Story Memory, and Figure Recall.
Low scores on this index indicate difficulties with recognition and retrieval of information from long-term memory stores This index is composed of both auditory and visual measures; therefore, a severe deficit in language, auditory processing, or visual functioning may impact one of the measures more than the other.
Analysis included the sum of the raw scores for each of the delayed memory subtests, with possible scores ranging from 0 to 62. Post Intervention data collection was on day 5 of treatment.
Post-Expansion (PE) appointments were not consecutive.
Mean time between enrollment and PE was 10 wks, longest was 43 wks.
|
Change from Baseline to Post-Intervention (after tDCS Session 5 - day 5 of treatment) and from Baseline to Post-Expansion (after the participant's final tDCS session beyond Session 5, up to 43 weeks).
|
|
Change in Overall Fluid Cognitive Abilities
Lasso di tempo: Change from Baseline to Post-Intervention (after tDCS Session 5 - day 5 of treatment) and from Baseline to Post-Expansion (after the participant's final tDCS session beyond Session 5, up to 43 weeks).
|
Cognitive function was determined using the NIH Toolbox-Cognition Battery computerized tests, specifically the Fluid composite score. It is derived by averaging the subtests in the Fluid domain to achieve an overall standard score. Fully Corrected T-scores are adjusted for for age, gender, race/ethnicity, and educational attainment. The score compares the score of the participant to those in the NIH Toolbox nationally representative normative sampling. The T-score has a mean of 50 in the general population and a SD of 10. Scores higher than the mean indicate better performance. Post Intervention data collection was on day 5 of treatment. Post-Expansion (PE) appointments were not consecutive. Mean time between enrollment and PE was 10 wks, longest was 43 wks. |
Change from Baseline to Post-Intervention (after tDCS Session 5 - day 5 of treatment) and from Baseline to Post-Expansion (after the participant's final tDCS session beyond Session 5, up to 43 weeks).
|
|
Cumulative Working Memory Effects of HD-tDCS Across Treatment Sessions
Lasso di tempo: Change from Baseline to Post-Intervention (after tDCS Session 5 - day 5 of treatment) and from Baseline to Post-Expansion (after the participant's final tDCS session beyond Session 5, up to 43 weeks).
|
The n-back test is a working memory task where participants identify stimulus that matches stimulus experienced "n" steps back. Participants performed a 2-back test, in which they were asked to remember and press a button when shown a stimulus that appeared 2 steps before the current one (e.g. square, circle, square). The number of correct and incorrect identifications are normalized (z-score). Total score is the z-score of correct button presses minus the z-score of incorrect button presses. A higher score (d') reflects better working memory performance. Possible scores range from -4.85 to 4.85. Positive change (increase) in 2-back score across treatment sessions indicates improvement in working memory performance. Data is shown as the mean slope calculation of participants across first 5 days of treatment and across all treatments, x=days of treatment, y=n-back score. Post-Expansion (PE) appointments were not consecutive. Mean time between enrollment and PE was 10 wks. |
Change from Baseline to Post-Intervention (after tDCS Session 5 - day 5 of treatment) and from Baseline to Post-Expansion (after the participant's final tDCS session beyond Session 5, up to 43 weeks).
|
|
Cumulative Memory Accuracy Effects of HD-tDCS Across Treatment Sessions
Lasso di tempo: Change from Baseline to Post-Intervention (after tDCS Session 5 - day 5 of treatment) and from Baseline to Post-Expansion (after the participant's final tDCS session beyond Session 5, up to 43 weeks).
|
Paired Associates task is a verbal memory task that asks participants to learn a list of word pairs. After a delay, participants are shown correct and mismatched word pairs one at a time and asked to identify if the displayed word pair was from the list they were asked to learn or not. Total accuracy is a proportion (total correct responses divided by total trials completed) ranging from 0 to 1 that measures the accuracy of a participant's responses to both correct and mismatched word pairs. Higher scores indicate better verbal memory performance, and positive changes over time indicate an improvement in verbal memory performance, measured after baseline (Session 1) and every intervention session (Sessions 2-5) Data is shown as the mean slope calculation of participants across first 5 days of treatment and across all treatments, x=days of treatment, y= total accuracy. Post-Expansion (PE) appointments were not consecutive. Mean time between enrollment and PE was 10 wks. |
Change from Baseline to Post-Intervention (after tDCS Session 5 - day 5 of treatment) and from Baseline to Post-Expansion (after the participant's final tDCS session beyond Session 5, up to 43 weeks).
|
|
Cumulative Memory Sensitivity Effects of HD-tDCS Across Daily Sessions
Lasso di tempo: Baseline
|
Verbal memory performance for computerized Paired Associates task, summarized with a computational model (linear ballistic accumulator decision model).
The model uses each participant's accuracy and reaction times across trials to estimate how efficiently they accumulate information to distinguish previously studied (target) word pairs from new (lure) pairs.
Reported outcome is the average memory sensitivity score at baseline, expressed as unitless model values (scores on a scale) where higher scores indicate better discrimination, scores near zero indicate chance-level performance, and negative scores (if present) indicate performance worse than chance.
|
Baseline
|
|
Tolerability of HD-tDCS
Lasso di tempo: Assessed immediately after each HD-tDCS session (participants received up to 30 sessions over approximately 1-12 weeks); values represent mean symptom burden averaged across all post-stimulation assessments
|
Tolerability was assessed using the HD-tDCS Safety Questionnaire, an 11-item symptom checklist.
The questionnaire assesses the presence (yes/no) of 10 specific self-reported symptoms (Itching, Burning, Tingling, Scalp Pain, Trouble Concentrating, Sleep problems, Headache, Mood Change, Neck Pain, and Other symptoms) and 1 oberserved symptom, Skin Redness.
Skin Redness was excluded from this analysis as it is not related to the participant's perception of tolerability.
The total score (symptom burden) was calculated by summing the number of symptoms present across the 10 items for each session.
Score range: 0 to 10 symptoms, where 0 = no symptoms present and 10 = all symptoms present.
Higher scores indicate worse tolerability (more symptoms experienced).
Values represent the mean number of symptoms per session, calculated by averaging symptom burden scores across all post-stimulation assessments within each treatment group.
|
Assessed immediately after each HD-tDCS session (participants received up to 30 sessions over approximately 1-12 weeks); values represent mean symptom burden averaged across all post-stimulation assessments
|
|
Effectiveness of Blinding of HD-tDCS
Lasso di tempo: Assessed immediately after each HD-tDCS session (participants received up to 30 sessions over approximately 1-12 weeks)
|
Participant's perception of treatment assignment assessed after each stimulation session using a 3-category ordinal scale.
Participants guessed whether they received: (0) Sham stimulation, (1) Don't Know, or (2) Active stimulation.
The scale is ordinal with Sham < Don't Know < Active.
Effective blinding is indicated by no significant difference in the distribution of perceived assignment between active and sham groups (i.e., participants in active groups cannot reliably distinguish their treatment from sham).
Higher proportional odds ratios would indicate active group participants were more likely to guess "active"; lower ratios would indicate sham participants were more likely to guess "active" (paradoxical pattern suggesting convincing sham condition).
|
Assessed immediately after each HD-tDCS session (participants received up to 30 sessions over approximately 1-12 weeks)
|
|
Change in Default Mode Network Connectivity
Lasso di tempo: Change from Baseline to Post-Intervention (after tDCS Session 5 - day 5 of treatment) and from Baseline to Post-Expansion (after the participant's final tDCS session beyond Session 5, up to 43 weeks).
|
The outcome focuses on default mode network (DMN) within-network functional connectivity. Within-network functional connectivity is estimated from fMRI data as strength of temporal coupling within DMN regions (nodes). For each participant and time point, correlation-based connectivity (Pearson r; Fisher r-to-z transformed; arbitrary units) was computed between DMN regions defined using a standard functional atlas. Higher values reflect stronger functional connectivity within DMN. A Z-score's range is infinite. Expected value is around -3 to 3. Analyses are conducted separately for amyloid negative (A-) and amyloid positive (A+) participants. Post Intervention data collection was on day 5 of treatment. Post-Expansion (PE) appointments were not consecutive. Mean time between enrollment and PE was 10 wks, longest was 43 wks. |
Change from Baseline to Post-Intervention (after tDCS Session 5 - day 5 of treatment) and from Baseline to Post-Expansion (after the participant's final tDCS session beyond Session 5, up to 43 weeks).
|
|
Cumulative Cognitive Change Across Daily Consecutive Sessions
Lasso di tempo: Change from Baseline to Post-Intervention (after tDCS Session 5 - day 5 of treatment) and from Baseline to Post-Expansion (after the participant's final tDCS session beyond Session 5, up to 43 weeks).
|
Measured through change in Cogstate or other comparable computerized cognitive testing scores across consecutive daily sessions.
|
Change from Baseline to Post-Intervention (after tDCS Session 5 - day 5 of treatment) and from Baseline to Post-Expansion (after the participant's final tDCS session beyond Session 5, up to 43 weeks).
|
|
Change in Global Cognition
Lasso di tempo: Change from Baseline to Post-Intervention (after tDCS Session 5 - day 5 of treatment) and from Baseline to Post-Expansion (after the participant's final tDCS session beyond Session 5, up to 43 weeks).
|
The Repeatable Battery of the Assessment of Neuropsychological Status (RBANS) is a comprehensive neuropsychological battery for the evaluation of global cognition and has been validated in subjects with mild cognitive impairment, moderate to severe traumatic brain injuries, vascular dementias, and Alzheimer's disease. Data was analyzed using the sum of the subtest raw scores, which is an indicator of the general cognitive functioning of the examinee. Low scores suggest general cognitive impairment even when some individual subtest scores may be within normal limits. Individuals with low scores on this measure exhibit problems with attention, memory, language, and construction skills. Possible scores range from 0 to 321. Post Intervention data collection was on day 5 of treatment. Post-Expansion (PE) appointments were not consecutive. Mean time between enrollment and PE was 10 wks, longest was 43 wks. |
Change from Baseline to Post-Intervention (after tDCS Session 5 - day 5 of treatment) and from Baseline to Post-Expansion (after the participant's final tDCS session beyond Session 5, up to 43 weeks).
|
Altre misure di risultato
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Modifica della capacità di inibizione
Lasso di tempo: Basale e post-intervento (dopo le sessioni tDCS 5 e 30)
|
Intenzione a priori di misurare attraverso il cambiamento nel punteggio del test di controllo inibitorio del fianco della cassetta degli attrezzi NIH
|
Basale e post-intervento (dopo le sessioni tDCS 5 e 30)
|
|
Cambiamento nella capacità di concettualizzazione
Lasso di tempo: Basale e post-intervento (dopo le sessioni tDCS 5 e 30)
|
A priori l'intento di misurare attraverso il cambiamento nel punteggio del test di ordinamento delle carte di cambiamento dimensionale NIH Toolbox
|
Basale e post-intervento (dopo le sessioni tDCS 5 e 30)
|
|
Modifica nella memoria della sequenza di immagini
Lasso di tempo: Basale e post-intervento (dopo le sessioni tDCS 5 e 30)
|
A priori l'intento di misurare attraverso il cambiamento nel punteggio del test di memoria della sequenza di immagini NIH Toolbox
|
Basale e post-intervento (dopo le sessioni tDCS 5 e 30)
|
|
Cambiamento nella capacità di memoria di lavoro
Lasso di tempo: Basale e post-intervento (dopo le sessioni tDCS 5 e 30)
|
A priori l'intento di misurare attraverso il cambiamento nell'elenco degli strumenti NIH che ordina il punteggio del test della memoria di lavoro
|
Basale e post-intervento (dopo le sessioni tDCS 5 e 30)
|
|
Modifica della velocità di elaborazione
Lasso di tempo: Basale e post-intervento (dopo le sessioni tDCS 5 e 30)
|
Intenzione a priori di misurare attraverso il cambiamento nel punteggio del test della velocità di elaborazione del confronto dei modelli NIH Toolbox
|
Basale e post-intervento (dopo le sessioni tDCS 5 e 30)
|
|
Cambiamento nel funzionamento visuospaziale
Lasso di tempo: Basale e post-intervento (dopo le sessioni tDCS 5 e 30)
|
Misurato attraverso la variazione del punteggio dell'indice visuospaziale RBANS
|
Basale e post-intervento (dopo le sessioni tDCS 5 e 30)
|
|
Cambiamento nel funzionamento della lingua
Lasso di tempo: Basale e post-intervento (dopo le sessioni tDCS 5 e 30)
|
Misurato attraverso la variazione del punteggio dell'indice linguistico RBANS
|
Basale e post-intervento (dopo le sessioni tDCS 5 e 30)
|
|
Cambio di attenzione
Lasso di tempo: Basale e post-intervento (dopo le sessioni tDCS 5 e 30)
|
Misurato attraverso la variazione del punteggio dell'indice di attenzione RBANS
|
Basale e post-intervento (dopo le sessioni tDCS 5 e 30)
|
|
Cambiamento nel funzionamento della memoria
Lasso di tempo: Basale e post-intervento (dopo le sessioni tDCS 5 e 30)
|
Misurato attraverso la variazione del punteggio dell'indice di memoria immediata RBANS
|
Basale e post-intervento (dopo le sessioni tDCS 5 e 30)
|
|
Cambiamento nel funzionamento cognitivo
Lasso di tempo: Basale e post-intervento (dopo le sessioni tDCS 5 e 30)
|
Intenzione a priori di misurare attraverso i cambiamenti nei punteggi subtest RBANS
|
Basale e post-intervento (dopo le sessioni tDCS 5 e 30)
|
Collaboratori e investigatori
Sponsor
Sponsor
Collaboratori
Collaboratori
Investigatori
Investigatori
- Investigatore principale: Benjamin Hampstead, PhD, Associate professor
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Effettivo)
Completamento primario
Completamento dello studio (Effettivo)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- HUM00146180
- 1R01AG058724 (Sovvenzione/contratto NIH degli Stati Uniti)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .